Atogepant monohydrate for the prevention of migraine


15 May 2024 - NICE has published final evidence-based recommendations on atogepant monohydrate (Aquipta) for preventing migraine in adults.

Atogepant monohydrate is recommended as an option for the prevention of migraine in adults who have at least four migraine days per month, only if at least three preventive medicines have failed.

Read NICE technology appraisal guidance 

Michael Wonder

Posted by:

Michael Wonder